HD-OPM Archive
Topics › Statins

Statins after high-risk prostate cancer diagnosis linked to 42% lower cancer death

Louis Nervegna · Dec 05, 2024 · ♥ 10 reactions · 9 comments · original Facebook post
StatinsCancer
AI summary & key facts

A shared summary of a cohort study of high-risk prostate cancer patients: post-diagnosis statin use (atorvastatin, pravastatin, rosuvastatin, not lovastatin) lowered prostate cancer mortality 42%, statins plus metformin 54%, and metformin alone showed no benefit.

#statinsHD #statinscancerHD #prostatecancerHD #atorvastatinHD #pravastatinHD #rosuvastatinHD #metforminHD

Research cited

—Taking a statin (atorvastatin, pravastatin, or rosuvastatin, but not lovastatin) alone after a diagnosis of high-risk prostate cancer reduced the risk of dying from prostate cancer by 42% compared to those who did not use statins or metformin.
—Taking metformin plus statins after their diagnosis was associated with a 54% reduction in dying from prostate cancer.
—Taking metformin alone did not show any reduction in prostate cancer mortality.

High‐risk prostate cancer was defined as: (T category ≥T2c or prostate specific antigen level ≥20 or Gleason score ≥8; equivalent to overall cancer stage ≥IIB)

← newer: Statins block an IL-33 inflammation pathway that may drive iolder: IV vitamin C plus chemotherapy doubled survival to 16 months →